A new Canada-based study has revealed that taking the diabetes drug Actos can increase a person’s odds of bladder cancer. The researchers who took part in the study reviewed well over 100,000 records of patients who were being treated with Actos between the years 1988 and 2009. Their review concluded that taking the diabetes drug doubled the risk of bladder cancer.
What Does the Company Have to Say?
Actos (or pioglitazone as it’s known generically) is manufactured by Takeda Pharmaceuticals, and a spokesperson for the company has said that Takeda is positive about the therapeutic benefits of the drug, and it is well aware of its value as a treatment for Type 2 diabetes. Additionally, the spokesperson noted that given the fact that Takeda is a science and evidence-based company, it confidently stands behind its considerable amount of data that confirms the positive risk/benefit profile of Actos.
Takeda has made particular note of its dedication to ongoing clinical research in order to understand and explore possible safety concerns, and the company is presently supporting a number of ongoing studies, to include a 10-year epidemiological study that is specifically looking into the possible relationship between bladder cancer and the drug, Actos.
Contact an Attorney if You’re Taking Actos and Have Concerns
The United States and Europe have put out warnings about the drug in the past; however, Actos remains on the market. That said, if you’ve been taking Actos and have some questions about its effects, you should speak to an attorney.
If you or someone you love has been the victim of a personal injury or accident, please contact Gersowitz, Libo & Korek, P.C. personal injury lawyers serving injured victims in New York and New Jersey at 800-LAW-9997.